NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Syntaxin Ltd

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biopharma Innovators Syntaxin Wins Top Honours at 2007 Interactive Media Awards - Biopharma firm Syntaxin's new website has won a very prestigious IMA award which recognises great design, technical innovation and accessibility compliance within the interactive media industry - Syntaxin.com
Biopharma Innovators Syntaxin Wins Top Honours at 2007 Interactive Media Awards

 

NewswireTODAY - /newswire/ - Abingdon, Oxon, United Kingdom, 2008/03/17 - Biopharma firm Syntaxin's new website has won a very prestigious IMA award which recognises great design, technical innovation and accessibility compliance within the interactive media industry - Syntaxin.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Cyber-Duck, an award winning web design company based in London and Hertfordshire offering corporate website design services, today announced that it has been awarded Outstanding Achievement in Website Development by the Interactive Media Awards for its work on the Syntaxin.com Website. The honour recognizes that the project met and surpassed the standards of excellence that comprise the web's most professional work. The site was honoured specifically for excellence in Medical and Science/Technology industries.

The judging consisted of various criteria, including design, usability, innovation in technical features, accessibility standards compliance and content. In order to win this award level, the site had to meet strict guidelines in each area - an achievement that very few websites submitted achieve.

Patrick Doyle, CEO of Syntaxin said, "Everyone at Syntaxin is delighted to be receiving this highly sought-after accolade as it reaffirms our belief that Syntaxin's new branding and website designed by Cyber-Duck better reflect Syntaxin as an industry leader. We hope that winning this award is simply the beginning of a fantastic 2008 in the biopharmaceutical and biotech industry for Syntaxin."

Award winning designers at Cyber-Duck commented, "We are extremely proud of the clean and professional look of the Syntaxin.com website design. Winning this award exemplifies how we managed to find the balance between powerful branding, eye-catching aesthetics, strong information architecture and accessibility compliancy."

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Syntaxin Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biopharma Innovators Syntaxin Wins Top Honours at 2007 Interactive Media Awards

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Patrick Doyle - Syntaxin.com 
+44(0)12 3555 2100 info[.]syntaxin.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Syntaxin Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Syntaxin Ltd / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
STEMCELL Technologies Joins BLOODPAC to Advance Pre-Analytical Best Practices for Liquid Biopsy
OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer
Ono Pharma Enters into a Drug Discovery Partnership with Mediar Therapeutics to Create Novel Antibody Therapeutics for Fibro-inflammatory Diseases
OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer
Ipsen Completes Acquisition of Memo Therapeutics AG, Adding First-in-class Asset to Ipsen’s Rare Disease Pipeline
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
IQIRVO® Demonstrates Statistically Significant Improvement in ALP Normalization in Patients with PBC in Phase IIIb ELSPIRE Study
Dysport® is the First Botulinum Toxin to Achieve Positive Topline Phase III Results in Both Episodic and Chronic Migraine
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
Ipsen to Acquire Memo Therapeutics AG - Adding First-in-class BK Polyomavirus Antibody, Expanding Rare Disease Portfolio
Ipsen to Acquire Kartos Therapeutics, Expanding Hemato-oncology Late-stage Pipeline
Ono Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 in Multiple System Atrophy At the 7th World Parkinson Con
Ipsen Announces Late-breaking Data from First Head-to-head Study Comparing Dysport® and Botox® in Adults with Upper Limb Spasticity

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  RightITnow, Inc.





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)